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  Cardiorenal syndrome (CRS) is the umbrella term used to 
describe clinical conditions in which renal dysfunction ac-
companies cardiac failure or cardiac dysfunction accompa-
nies renal failure [1, 2]. There are 5 types of CRS (Table 1). 
The rising prevalence of chronic kidney disease (CKD) and 
heart failure (HF), contributed to the increase of the inci-
dence of CRS, which was further increased by the improved 
survival of patient with HF, CKD or both [3, 4]. The hetero-
geneous and complex pathophysiology of CRS makes effec-
tive patient management difficult. Established therapeutic 
strategies, such as diuretics, are often associated with resis-
tance and limited clinical success [3, 5].  
 Fabian  et al. [6] provide useful data about CRS. The per-
centage of patients with the syndrome is relatively high 
among patients admitted in an Internal Medicine Ward (1 in 
7 patients). In CRS, HF and CKD shared a substantial num-
ber of risk factors [6], such as old age, arterial hypertension, 
diabetes mellitus (DM), and history of cardiovascular disease 
(CVD) [6].  
  Despite the fact that Fabian et al. do not report mortality 
rates they support that "women with glomerular filtration 
rate (GFR) 30-44 ml/min/1.73m
2 and men with GFR 30-50 
ml/min/1.73m
2 but without history of CVD had a hazard 
ratio for CVD of 1.51 that increased to 2.39 in those with 
CVD history. Worsening of renal function is also an inde-
pendent predictor of mortality in acute decompensated heart 
failure (ADHF)." Moreover, it has been established that in-
dividuals with CKD are more likely to die of CVD than to 
develop kidney failure [7]. Thus, given the poor prognosis of 
CRS [3,5] Fabian et al. suggest that prevention is a priority 
[8]. 
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  Some of the measures of CRS prevention are focused, 
according to CRS type, on preventing decompensation of 
stable HF, optimal medical and device treatment of HF with 
blood pressure and volume control, prevention of acute renal 
injury (AKI), attenuating the progression of CKD, and 
treatment of the underlying systemic disease to reduce end-
organ injury [3,5]. 
  CRS is a haemodynamic derangement ranging from acute 
pulmonary oedema, with hypertension through severe pe-
ripheral fluid overload, to cardiogenic shock and hypoten-
sion [9]. However, its pathophysiology is much more com-
plex than simply reduced cardiac output or renal dysfunc-
tion. Factors such as nitric oxide, prostaglandin, natriuretic 
peptides, and endothelin may mediate renal perfusion inde-
pendently of cardiac haemodynamics and vice versa [10]. 
  There are some "established" measures for the prevention 
or the treatment of CRS. One of these is renin-angiotensin-
aldosterone system (RAAS) blockade [5]. Many trials con-
firmed the benefits of angiotensin enzyme inhibitors (ACEI), 
such as Studies of Left Ventricular Dysfunction (SOLVD), 
in the treatment of HF [11]. However, SOLVD excluded 
patients with serum creatinine concentrations > 2.0 mg/dL. 
The Cooperative North Scandinavian Enalapril Survival 
Study (CONSENSUS) [12] in patients with severe HF, in-
cluded patients with renal impairment, but only if their se-
rum creatinine concentrations were < 3.4 mg/dl. Although 
only a minority of patients in CONSENSUS had creatinine 
levels > 2.0 mg/dL, this subgroup showed evidence of im-
proved outcomes when treated with an ACEI [12]. Some of 
those experienced a serum creatinine increased by 30% or 
greater with enalapril [12]. However, creatinine tended to 
stabilize and in many patients improved throughout the 
study. Therefore, it has been suggested that RAAS blockade 
may be carefully titrated provided that serum creatinine does 
not continue to rise beyond 30% and potassium is constantly 
< 5.0 mmol/L [13]. ACEI therapy in patients with baseline 
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benefits [14], and unless contraindicated, should be routinely 
used [5]. Most patients who are already on an ACEI and de-
velop renal insufficiency during hospitalization for HF de-
compensation should not have their ACEI stopped. In gen-
eral, ACEI use is not associated with worsening renal func-
tion in these patients [15]. However, clinical judgment 
should be used in patients with cardiogenic shock or acute 
renal failure [14].  
  Blockade of the sympathetic system with beta-blockers is 
another important strategy for patients with congestive HF or 
CHD [13]. In general, these drugs should not adversely af-
fect kidney function. Certain beta-blockers may be relatively 
contraindicated in CKD because of metabolism by the kid-
ney, such as atenolol, nadolol or sotalol [16]. Carvedilol has 
been demonstrated to have favourable effects on kidney 
function in some CRS patients, and may have a benefit over 
older beta-blockers [17]. 
  Both congestive HF and CKD are associated with anae-
mia, the latter of which is commonly treated with erythro-
poiesis-stimulating agents [18], and there is interest in using 
erythropoiesis-stimulating agents in HF patients [19]. How-
ever, other studies did not find significant improvement in a 
variety of important clinical parameters [20]. Moreover, the 
Trial to Reduce Cardiovascular Events with Aranesp Ther-
apy (TREAT) [21] reported that patients with a poor re-
sponse to darbepoetin alfa, compared with those with a better 
response, had higher rates of the composite CVD end point 
[adjusted hazard ratio (HR), 1.31; 95% confidence interval 
[CI], 1.09 to 1.59) or death (adjusted HR, 1.41; 95% CI, 1.12 
to 1.78), as doses were increased to attain target haemoglo-
bin levels. These findings raise concern about current strate-
gies for treating anaemia in patients with CKD [21]. 
  However, it seems that there is a treatment that poten-
tially improves both cardiac and renal function and practi-
cally remains unused in the effort to prevent CRS: effective 
statin treatment with a specific compound at specific doses 
[22].  
  It was shown in a post hoc analysis of the Treating to 
New Targets (TNT) study (n = 10,001) that 80 mg/day of 
atorvastatin compared with the 10 mg/day dose, in patients 
with stable coronary heart disease (CHD) significantly re-
duces hospitalizations for HF [23]. However, this benefit 
was mainly shaped by CHD patients with a history of HF 
(7.8% of study population) [23]. In this subgroup the inci-
dence of hospitalizations was substantially less in the 80 
mg/day group than those with a 10 mg/day group [17.3 vs 
10.6% in the 10- and 80-mg arms, respectively (HR 0.59; 
95% CI 0.4 to 0.88; P=0.009)] [23]. Similar were the results 
of the GREek Atorvastatin and Coronary-heart-disease 
Evaluation (GREACE) study [24] that we reported 5 years 
earlier than TNT. A post hoc analysis of the Scandinavian 
Simvastatin Survival Study (4S) in 1997 [25] showed that 
mortality was 31.9% in the placebo group and 25.5% in the 
simvastatin group among patients who developed HF. These 
Table 1.  Types of Cardiorenal Syndrome 
Type of Cardiorenal Syndrome  Definition  Primary Event 
Acute cardio-renal (type 1) (20–25%) 
 
Acute worsening of heart function (AHF–ACS) 
leading to kidney injury and/or dysfunction 
Acute heart failure (AHF) or acute coronary 
syndrome (ACS) or cardiogenic shock 
Chronic cardio-renal (type 2) (30–45%) 
 
Chronic abnormalities in heart 
function (CHF-CHD) leading to 
kidney injury or dysfunction 
Chronic heart disease (systolic and/or  
diastolic dysfunction, chronic 
abnormalities in cardiac function,  
cardiomyopathy) 
Acute reno-cardiac (type 3) (30–35%) 
 
Acute worsening of kidney function leading to 
heart injury and/or dysfunction 
Acute kidney injuring (AKI)  
Chronic reno-cardiac (type 4) (45–50%) 
 
Chronic kidney disease (CKD) leading to heart 
injury, disease and/or dysfunction 
 
CKD 
Secondary cardio-renal (type 5) 
 
Systemic condition causing cardiac and renal dys-
function 
Systemic disease (septic shock, diabetes, MetS, 
NAFLD, amyloidosis, vasculitis etc.) 
AHF = Acute heart failure, ACS = acute coronary syndrome, AKI = acute kidney injury, CKD = chronic kidney disease, MetS = Metabolic syndrome, NAFLD = non alcoholic fatty 
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were substantially higher than the mortality rates of non-HF 
patients (9.2 and 6.6%, respectively), however, the reduction 
in mortality and hospitalizations were comparable among HF 
and non-HF patients [25]. Still, this is the heart end of the 
CRS. The issue is to cover both the heart and kidney. 
  Early CKD (up to stage 3; the stages of CKD are reported 
in Table 2) could be slowed down [26] or even reversed by 
statins which on the other hand substantially reduce CVD 
events [22, 27-30]. Uncontrolled dyslipidaemia induces a 
renal function impairment that ranges from 1 to 12 
ml/min/1.73m
2 per year, particularly in the presence of dia-
betes (DM) or arterial hypertension [27,29]. A large study 
with 40 mg/day of simvastatin (the Heart Protection Study, 
n=20,000) [31] and a joint analysis of pravastatin trials [32] 
showed that these statins reduce the rate of the (expected 
with age and CVD risk factors) kidney function decline in 
patients with or at risk of CVD. In the GREACE study, we 
showed for the first time that atorvastatin treatment signifi-
cantly increases eGFR. In contrast, eGFR was reduced in 
untreated patients with CHD with or without metabolic syn-
drome (MetS) or DM [33-35]. This improvement of renal 
function was clinically relevant and associated with substan-
tially reduced CVD events [33]. With every 5% in eGFR 
increase there was a reduction of 16% in clinical vascular 
events, after multiple regression analysis adjusting for major 
covariates [33]. Thus, with a 10% increase of eGFR in stage 
2 and 3 CKD patients in GREACE we recorded a 32% fur-
ther (independent of LDL-C) reduction in clinical events 
[33]. A substantial benefit of atorvastatin treatment was also 
seen in the large TNT trial (n = 10,001 patients with stable 
CHD) [36,37]. In stage 3 CKD TNT patients, the increase in 
eGFR was significantly greater with atorvastatin 80 mg/day 
than with 10 mg/day (9.9 vs 6.6%, respectively; p < 0.005) 
[36]. In patients with stage 3 CKD (n = 3,107) the HR for 
CVD events was 31.9% higher than those without CKD (n = 
6,549), regardless of atorvastatin dose [36]. Nevertheless, 
compared with atorvastatin 10 mg/day, the 80 mg/day dose 
reduced the relative risk of major CVD events significantly 
more in those with CKD (by 32 vs 15% in those with normal 
renal function) [37] This reduction shaped the overall TNT 
outcome and was identical with the one we recorded in 
GREACE [33]. In the Collaborative Atorvastatin Diabetes 
Study (CARDS) [38], a randomized placebo-controlled trial 
that included 2,838 patients with type 2 DM and free of 
CVD at baseline, 34% of the patients had stage 3 CKD 
(eGFR of 30-59 ml/min/1.73m
2-Table 2). In these patients 
atorvastatin 10 mg/day was associated with a moderate im-
provement in the annual change in eGFR (p = 0.01). This 
was accompanied by a substantial reduction in major CVD 
events (total mortality plus non-fatal myocardial infarction: -
42%) and stroke (-61%) [38], compared with placebo.  
  In GREACE, TNT and CARDS, the control of other 
CVD risk factors (except dyslipidaemia) was similar in the 
atorvastatin and placebo (or usual care for GREACE) 
groups; therefore the improvement in renal function and the 
clinical benefit in terms of CVD event reduction is attributed 
to atorvastatin use. This stage 3 CKD patient group is a sub-
stantial part of secondary prevention patients (32 to 34% in 
all 3 of the studies above) and benefited most from lipid-
lowering in all 3 studies. In the above studies in patients ef-
fectively treated with statins there were less acute coronary 
events (less ground for type 1 CRS), less cases with conges-
tive HF (less ground for type 2 CRS) and fewer cases with 
CKD, because statin treatment halted the evolution of kidney 
impairment or even reversed it. Thus, there was less ground 
for type 4 CRS and if CKD is the perfect substrate for acute 
kidney impairment after haemodynamic derangement, less 
ground for type 3 CRS. Even type 5 CRS could be pre-
vented, at least in part, with statin treatment. There is a posi-
tive impact of managing atherogenic dyslipidaemia on CVD 
outcome across all stages of diabetic nephropathy [29], MetS 
[39], non alcoholic fatty liver disease (NAFLD) [40], or sys-
temic autoimmune diseases (SAD) [41]. CVD is the leading 
cause of morbidity and mortality in patients with SADs [42]. 
Patients with systemic lupus erythematosus (SLE) are 5-6 
times more likely to have a significant coronary event than 
the general population [43]. Rheumatoid arthritis (RA) is 
also associated with an increased CVD risk resulting in early 
mortality and excess morbidity [42-44]. However these dis-
eases also affect renal function [45]. Both CVD and CKD 
might be effectively managed, to some extent, by statins [42] 
Both CVD and CKD in the above diseases are related to low 
grade inflammation, endothelial dysfunction-low NO levels, 
oxidative stress, instability of atherosclerotic plaques and a 
pro-coagulant state related to atherosclerosis [41,46]. There 
is evidence that these factors could be controlled by the plei-
otropic (cholesterol-lowering-independent) effects of statins 
[46]. These effects are enhanced by even a small increase  
in high density lipoprotein cholesterol levels [47], and are 
evident even in patients with mild renal impairment [48].  
  All the above suggest that the use of ACEI and statins 
might be an effective regimen to prevent a substantial num-
Table 2.  Stages of Chronic Kidney Disease 
  Description  GFR 
ml/min/1.73m
2 
Stage 1  Kidney damage with normal or increased GFR   90 
Stage 2  Kidney damage with mildly decreased GFR  60-89 
Stage 3  Moderately decreased GFR  30-59 
Stage 4  Severely decreased GFR  15-29 
Stage 5  Kidney failure  < 15 or dialysis 
GFR = glomerular filtration rate. Chronic Kidney Disease Increases Vascular Risk  The Open Cardiovascular Medicine Journal, 2011, Volume 5    229 
ber of CRS cases in high risk patients and improve survival 
and quality of life in these people. There are data suggesting 
that combined use of a statin plus an ACEI improves clinical 
outcome more than a statin alone and considerably more 
than an ACEI alone [30]. After all, recent guidelines suggest 
that CKD is a high CVD risk situation [49,50]. This requires 
aggressive statin treatment.  
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